Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with ...

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price hoisted by equities researchers at Leerink Partners ...

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common ...

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting as book-running manager for the proposed offering. An automatically ...

The decline in 89bio's stock price reflects investor reaction to the potential dilution of shares due to the proposed offering. When a company issues additional stock, it can lead to a reduction in ...

Goldman Sachs & Co (NYSE:GS). LLC, Leerink Partners, and BofA Securities are leading the offering as book-running managers, with Cantor also serving as a book-running manager. The announcement ...

SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...